Kevin Sweet, MS, CGC
Phone:  614-293-6694
Fax: 614-293-2314
kevin.sweet@osumc.edu   

Sweet, K., Bradley, T., Westman, J.  Identification and referral of families at high risk for cancer susceptibility.  J Clin Oncol 2002; 20(2): 528-37.

Sweet K, Willis, S, Asida, S and Westman, JA.  Use of Fear Appeal Techniques in the Design of Tailored Cancer Risk Communication Messages:  Implications for Health Care Providers.  J Clin Oncol, 2003; 21(18); 3375-3376.

Lynch HT, Coronel SM, Okimoto R, Hampel H, Sweet K, Lynch JF, Barrow A, Fodde R, Wagner A, Wijnen J, van der Klift H, Franken P, de la Chapelle A. An American founder mutation of the MSH2 gene identified in various areas of the United States and possibly accounting for a significant proportion of all Lynch Syndrome.  JAMA, 2004 Feb 11; 291(6):718-24.

Hampel H, Sweet K, Westman JA, Offit K, Eng C. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria.  J Med Genet 41(2):81-91, Feb 2004.

Nagy R, Sweet K, Eng C. Invited Review: Highly penetrant hereditary cancer syndromes. Oncogene, 2004; 23, 6445–6470.

Sweet, K, Lynch, H.  Genetic Aetiology of Diffuse Gastric Cancer: So Near, Yet so Far.  Invited Editorial, J Med Genet, 2004 Jul;41(7):481-3.

Sweet, K., Willis, J, Sawada, T, Zhou, X.P., Gallione, C., Alhopuro, P., Khoo, S.K., Martin, C., Bridgeman, S., Heinz, J., Pilarski, R., Lehtonen, R., Prior, T.W., Marchuk, D.A., Frebourg, T., Teh, B.T., Aaltonen, L., Eng, C.  Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis.  JAMA, 2005 Nov 16;294(19):2465-73.

Narod, S., Lubinski, J., Ghadirian, P., Lynch, H.T., Moller, P., Foulkes, W., Rosen, B., Kim-Sing, C., Isaacs, C., Domchak, S., Sun, P., Hereditary Breast Cancer Clinical Study Group (Wagner, T., Ainsworth, P., Chudley, A., Eisen, A., Golcrist, D., Lemire, E., Provencher, D., Pasini, B., Bellati, C., Couch, F., Daly, M., Eng, C., Fishman, D., Karlan, B., McLennan, J., McKinnon, W., Merajver, S., Neuhasen, S., Pasche, B., Olopade, O., Osborne, M., Sweet, K., Saal, H., Tung, N., Weitzel, J., Wood, M.)  Screening mammography and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.  Lancet Oncol. 2006 May;7(5):402-6.

Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA, and the Hereditary Breast Cancer Clinical Study Group (D Gilchrist, D., Weber, B., Rebbeck, T., Isaacs, C., Neuhausen, S., Garber, J., Karlan, B., Fishman, D., Merajver, S., McKinnon, W., Wood, M., Evans, G., Moller, P., B. Pasini, B., Sweet, K., Eng, E., G. Rennert, G., Couch, F., McLennan, J., and Provencher, D.)  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.  Int J Cancer. 2006 May 1;118(9):2281-4.

Kelly, K. and Sweet, K.  In Search of a Familial Cancer Risk Assessment Tool.  Invited   Review, Clin Genet 2007: 71:  76-83.

Allain, D., Sweet, K. and Agnese, D.  Management Options After Prophylactic Surgeries in Mutation Positive BRCA Patients:  A Review.   Cancer Control.  Oct. 2007, Vol. 14, No. 4:  220-227.